Dr. Bruce Wilcox profile page

Chief Technology Officer

at PrognomiQ

Bruce Wilcox is the Chief Technology Officer of PrognomiQ. Previously, he was Chief Executive Officer and Founder of DiscernDx. Prior to this, he was Senior Vice President, Research and Development for Applied Proteomics, where he developed and launched the SimpliPro Colon test, a proteomic blood-based test for colon cancer. Earlier in his career, Bruce had multiple R&D leadership roles at Applied Minds, Eksigent Technologies, Nanostream, and Hamilton Sundstrand Sensor Systems, where he supported the development and commercialization of mass spectrometry instruments and systems in multiple applications. Bruce received his Ph.D. in Analytical Chemistry from the University of New Mexico, and his B.S. in Chemistry from North Dakota State University.

Got a Question for Dr. Bruce Wilcox?

Get in touch using the contact form linked here and we’ll get back to you shortly.

Published Content

Total: 1

Webinar

Plasma Proteome Profiling for Lung Cancer Biomarker Discovery

On-Demand

In this webinar, you’ll hear how one of the largest multiomics observational studies to date has revealed lung cancer biomarkers from the blood plasma proteome. Our expert speakers will discuss how the research sheds new light on early-stage lung cancer diagnostics and clinical outcomes and showcase how multiomics approaches are key for characterizing complex diseases.